Thomasf Imperiale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Screening for colorectal cancer presents a unique opportunity unavailable for most other types of cancers. Screening allows for the detection of both precancerous polyps and cancer, enabling clinicians to intervene and reduce the chances of future development of new or more advanced malignancy. However, gaps in the colorectal screening process exist. One of the most critical gaps, according to an editorial published in JAMA Network Open by Regenstrief Institute Research Scientists Jennifer Maratt, M.D., M.S., and Thomas Imperiale,M.D., and Duke University colleague David A. Leiman, M.D., MSHP,...

A next-generation multitarget stool DNA test for colorectal cancer screening had higher sensitivity but lower specificity than a currently available FIT, according to the large prospective BLUE-C study.

Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included...

<p>A recent study by Regenstrief Institute, Indiana University School of Medicine, University of Alabama at Birmingham and University of North Carolina, Chapel Hill, researcher-clinicians is one of the first to identify and evaluate colorectal cancer screening programs in Latin America.</p> <p>The research team made several significant findings including the lack of screening programs in low-middle-income countries, such as Honduras, El Salvador, Guatemala and Bolivia. The researchers also found the prevalence of colorectal cancer in high-middle-income countries, such as Braz...

Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.